Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs
about
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersStructural Studies of G Protein-Coupled ReceptorsLarge-scale production and protein engineering of G protein-coupled receptors for structural studiesNovel Allosteric Modulators of G Protein-coupled ReceptorsGeneric GPCR residue numbers - aligning topology maps while minding the gapsStructural basis of Smoothened regulation by its extracellular domainsStructure-Based Sequence Alignment of the Transmembrane Domains of All Human GPCRs: Phylogenetic, Structural and Functional ImplicationsSmoothened goes molecular: new pieces in the hedgehog signaling puzzleG protein-coupled receptors in cardiac biology: old and new receptorsDesign, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.Crystal structure of a multi-domain human smoothened receptor in complex with a super stabilizing ligandSmoothened Regulation: A Tale of Two Signals.The Hedgehog pathway effector smoothened exhibits signaling competency in the absence of ciliary accumulation.Residues remote from the binding pocket control the antagonist selectivity towards the corticotropin-releasing factor receptor-1.MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.Functional Divergence in the Role of N-Linked Glycosylation in Smoothened SignalingSynthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics.Identification of Novel Smoothened Ligands Using Structure-Based Docking.Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.Hedgehog signalling does not stimulate cartilage catabolism and is inhibited by Interleukin-1βI only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugsTowards a structural understanding of allosteric drugs at the human calcium-sensing receptorCholesterol activates the G-protein coupled receptor Smoothened to promote Hedgehog signaling.Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas.7TM Domain Structure of Adhesion GPCRs.Wnt signaling in triple-negative breast cancer.Hedgehog associated to microparticles inhibits adipocyte differentiation via a non-canonical pathway.Sonic Hedgehog Activates Phospholipase A2 to Enhance Smoothened Ciliary Translocation.Agonist-induced dimer dissociation as a macromolecular step in G protein-coupled receptor signaling.Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: meeting new challenges.Assessment of the transmembrane domain structures in GPCR Dock 2013 models.Discovery of new GPCR ligands to illuminate new biology.Multiple ligand binding sites regulate the Hedgehog signal transducer Smoothened in vertebrates.A Structural Framework for GPCR Chemogenomics: What's In a Residue Number?Current and Future Challenges in GPCR Drug Discovery.Comprehensive Analysis of Non-Synonymous Natural Variants of G Protein-Coupled Receptors.Structure-based prediction of Wnt binding affinities for Frizzled-type cysteine-rich domains.A synthetic combinatorial approach to disabling deviant Hedgehog signaling.Hypomorphic Smo mutant with inefficient ciliary enrichment disrupts the highest level of vertebrate Hedgehog response.
P2860
Q26748728-AEA5BA13-C591-4E1C-A328-4DA97C70BA2DQ26783016-4A8BB9D0-1033-4E24-9630-56528C3AA038Q26866010-61EF093C-3145-4AB2-A08C-0A282967C6A5Q28081112-583C17D4-CB02-466B-8E00-4E318E3F04EDQ28087587-46C388A1-97FF-407E-841F-BDC8EBB89629Q28277263-FF711223-24C0-4AE9-88C8-56FC69B12790Q28551072-A2609F8B-EAAD-46C5-BC3A-E79EE399EC0BQ33359720-5B1F1CA2-C198-4B79-921A-198CA4022AB1Q33639685-BEB63DDE-5A35-4C9B-9E46-38760A963103Q33687409-BDE458E0-C111-4428-B59F-C5682E0548C8Q33721053-25276051-E035-40DB-AAC0-AB9B60DC0B41Q34496658-0637E6FE-25E6-47D8-BACF-61DA9E963DF6Q34747353-73D1A9C7-2FA7-4187-ABF6-1595F3F3A55EQ35020584-9A352859-12BF-45F3-A574-C605A11BBA30Q35552174-2FF8F78A-C57B-487B-BEE4-1D6A271792CEQ35671396-D02D75C7-14C4-4808-A1C2-95005D391C5DQ35751142-1BBCE5D2-590A-429F-A9DA-324A4F6EBFDFQ35756696-CCA060E9-5E93-4A4F-B3C2-5AE5BECF51DDQ36094653-EA3B1326-DF9A-4594-86F9-886CD48DE3D0Q36207322-B6640532-E071-4D98-A1F3-39F70B832DBDQ36477430-693B6E9F-FBB1-4484-AFD9-2EBD966C275DQ36869422-F6085642-8B71-4C2D-A2D6-53DF36A7E308Q36869965-3AEDACD3-5C04-4219-9B97-38912691E339Q37441853-E8A97311-2B4C-48E4-8D5E-E585A6AB1BF0Q37714065-0B72DABC-C0F5-4278-8A51-F2F25905B08FQ39004681-5B74E02C-C407-4C16-AB8B-6E7CB42DFC1CQ39214992-76001E63-7CCD-4536-8207-9A61FC0FAC02Q39449375-C136CCED-705E-4781-A1CF-22C6AAA129A3Q40181455-A922C443-5F41-4DEB-93DF-68E29CFF85F1Q41308798-074D70A2-E2DF-452F-B7DA-8FFB8ECB5A29Q42091180-5099BBF6-173D-4031-BA59-84A71A1CA7F4Q46253588-F6998B8C-F6EC-48D9-9B47-9BC8ACB93C3EQ46344527-9DFDF823-4EAD-4B4F-9710-AECA0F4F7901Q47264652-8B60EA84-510C-4B4A-894C-4588567BCF52Q47348737-E06608DD-34DD-4195-A6A1-7B3A679EDDE8Q47348761-73B72E5F-A30A-4FBC-AB84-7FF1B236A8BCQ47766242-975FEEBA-712E-45E0-89BD-B62E9C27A95FQ48114249-A94CE9F7-6F46-48FB-B597-F5BF5ABE351AQ48215997-3A0D5587-92A7-4DB8-B30B-B62BFD750F8BQ52639896-F3475C45-842E-412A-8A25-C2C5C63CDB3E
P2860
Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Structural basis for Smoothene ...... resistance to anticancer drugs
@ast
Structural basis for Smoothene ...... resistance to anticancer drugs
@en
Structural basis for Smoothene ...... resistance to anticancer drugs
@nl
type
label
Structural basis for Smoothene ...... resistance to anticancer drugs
@ast
Structural basis for Smoothene ...... resistance to anticancer drugs
@en
Structural basis for Smoothene ...... resistance to anticancer drugs
@nl
prefLabel
Structural basis for Smoothene ...... resistance to anticancer drugs
@ast
Structural basis for Smoothene ...... resistance to anticancer drugs
@en
Structural basis for Smoothene ...... resistance to anticancer drugs
@nl
P2093
P2860
P50
P3181
P356
P1476
Structural basis for Smoothene ...... resistance to anticancer drugs
@en
P2093
Bryan L Roth
Chong Wang
Dan J Urban
Eyal Vardy
Gye Won Han
Marc G Caron
Sandy J Hufeisen
Tama Evron
Thomas J Mangano
P2860
P2888
P3181
P356
10.1038/NCOMMS5355
P407
P577
2014-07-10T00:00:00Z
P6179
1045497145